Enliven Therapeutics (NASDAQ:ELVN) Trading Down 7% – Should You Sell?

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price traded down 7% during trading on Thursday . The company traded as low as $22.40 and last traded at $22.40. 61,547 shares traded hands during trading, a decline of 76% from the average session volume of 253,275 shares. The stock had previously closed at $24.08.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Robert W. Baird raised their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a research note on Friday. They issued a “buy” rating and a $42.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Enliven Therapeutics has a consensus rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Trading Up 0.7 %

The firm has a 50 day moving average price of $26.65 and a two-hundred day moving average price of $24.16. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -12.18 and a beta of 1.02.

Insider Buying and Selling

In other Enliven Therapeutics news, CEO Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $27.50, for a total transaction of $75,075.00. Following the sale, the chief executive officer now directly owns 1,033,793 shares in the company, valued at $28,429,307.50. The trade was a 0.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $24.89, for a total value of $130,672.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 129,195 shares of company stock valued at $3,581,772. Corporate insiders own 29.20% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ELVN. FMR LLC increased its holdings in Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares during the last quarter. First Turn Management LLC purchased a new stake in Enliven Therapeutics during the 2nd quarter worth approximately $9,657,000. Lord Abbett & CO. LLC bought a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $8,199,000. Janus Henderson Group PLC increased its holdings in shares of Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after acquiring an additional 313,019 shares during the last quarter. Finally, Ally Bridge Group NY LLC bought a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $5,998,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.